FDA Approves New Fibrinogen Concentrate for Congenital Fibrinogen Deficiency ...

Fibryga (R) is now approved in the U.S. for fibrinogen supplementation in both congenital and acquired fibrinogen deficiency, and is available in 1-gram and 2-gram kits, each with the nextaro (R) ...

What Is Fesilty, and Why Does It Matter? Fesilty (fibrinogen, human-chmt) is a newly approved treatment for sudden bleeding episodes in both children and adults with a rare condition called congenital ...

Fibryga is a human plasma-derived fibrinogen concentrate authorised for AFD in the US.

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ...

PARAMUS, N.J, Aug. 1, 2024 /PRNewswire/ -- Octapharma USA, Inc. has announced the expanded approval of fibryga ®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement ...

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency 10.06.2022 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS ...

PARAMUS, N.J., Jan. 7, 2026 /PRNewswire/ -- Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation of Fibryga ®, Fibrinogen (Human ...